ArticleNature communications2024
Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
30.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 81 citations in OpenAlex.
- Secreted ORF8 reprograms macrophages to enhance SARS-CoV-2 infection of lung epithelial cells.Science advances · 2026Article
- GC content mismatch of transgene destabilizes RNA virus genomes.Journal of virology · 2026Article
- Secreted ORF8 reprograms macrophages to enhance SARS-CoV-2 infection of lung epithelial cells.bioRxiv : the preprint server for biology · 2026Article
- Programmable antibody-based chimeric entry receptors for sarbecoviruses.Communications biology · 2026Article
- Impact of Early COVID-19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database.Immunity, inflammation and disease · 2026Observational
- Collectin-11, a complement pattern recognition molecule, mediates pulmonary SARS-CoV-2 neutralization and protection.PLoS pathogens · 2026Article
- Comparative genomics identifies small interfering RNA with activity against all five human betacoronaviruses.Genome medicine · 2026Article
- Rapid immunization and antibody redesign platform discovers broadly neutralizing antibodies against non-immunized SARS-CoV-2 variant.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Conservation of Bacterial Lipopolysaccharide Binding by SARS-CoV-2 Spike across Major Viral Variants.Computational and structural biotechnology journal · 2026Article
- Age-dependent immune profiles and variant-driven humoral alterations across two SARS-CoV-2 epidemic phases.Frontiers in immunology · 2026Article
- SARS-CoV-2 variants: biology, pathogenicity, immunity and control.Nature reviews. Microbiology · 2026Review
- Comprehensive whole-genome characterization of SARS-CoV-2 strains in Jining China 2024-2025.Frontiers in microbiology · 2026Article
- A tale of SARS-CoV-2 genomic surveillance in Mali: Variants introductions and transmission dynamics.PloS one · 2026Article
- Impacts of neutralizing antibody responses on SARS-CoV-2 evolution and its associated disease progression.Immunity & inflammation · 2026Article
- SARS-CoV-2 ORF8: an accessory protein at the interface of immune evasion and inflammation.Frontiers in immunology · 2026Review
- Increased pathogenicity and transmission of SARS-CoV-2 Omicron XBB.1.9 subvariants, including HK.3 and EG.5.1, relative to BA.2.Journal of virology · 2025Article
- A non-spike nucleocapsid R204P mutation in SARS-CoV-2 Omicron XEC enhances inflammation and pathogenicity.Nature communications · 2025Article
- Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccines.Nature communications · 2025Article
- Article
- A SARS-CoV-2 entry inhibitor trimerizes to lock the spike protein in a closed conformation.bioRxiv : the preprint server for biology · 2025Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 14 institutions in 2 countries.
Tomokazu Tamura *Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.ORCID 0000-0003-1395-6610
Takashi Irie *Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID 0000-0003-3765-8482
Sayaka Deguchi *Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
Hisano Yajima *Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.ORCID 0009-0000-0065-4125
Masumi Tsuda *Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.ORCID 0000-0001-5400-5905
Hesham Nasser *Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.ORCID 0000-0001-9163-1665
Keita Mizuma *Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Arnon Plianchaisuk *Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0009-0004-2416-0508
Saori Suzuki *Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.ORCID 0000-0001-5233-6604
Keiya UriuDivision of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Mst Monira BegumDivision of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Ryo ShimizuDivision of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Michael JonathanDivision of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.ORCID 0000-0001-9640-1420
Rigel SuzukiDepartment of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Takashi KondoSchool of Medicine, Hokkaido University, Sapporo, Japan.
Hayato ItoGraduate School of Medicine, Hokkaido University, Sapporo, Japan.
Akifumi KamiyamaGraduate School of Medicine, Hokkaido University, Sapporo, Japan.
Kumiko YoshimatsuInstitute for Genetic Medicine, Hokkaido University, Sapporo, Japan.ORCID 0000-0002-0062-2753
Maya ShofaDepartment of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan.
Rina HashimotoCenter for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.ORCID 0000-0002-7174-4563
Yuki AnrakuLaboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.ORCID 0000-0002-5731-0902
Kanako Terakado KimuraLaboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Shunsuke KitaLaboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.ORCID 0000-0003-3969-302X
Jiei SasakiLaboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Kaori Sasaki-TabataDepartment of Medicinal Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Katsumi MaenakaOne Health Research Center, Hokkaido University, Sapporo, Japan.ORCID 0000-0002-5459-521X
Naganori NaoInstitute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan.
Lei WangDepartment of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.ORCID 0000-0001-6145-395X
Yoshitaka OdaDepartment of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Genotype to Phenotype Japan (G2P-Japan) Consortium
Terumasa IkedaDivision of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.ORCID 0000-0003-2869-9450
Akatsuki SaitoDepartment of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0002-2792-4399
Keita MatsunoInstitute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan.ORCID 0000-0002-4205-6526
Jumpei ItoDivision of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-0440-8321
Shinya TanakaDepartment of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan. tanaka@med.hokudai.ac.jp.ORCID 0000-0001-6470-3301
Kei SatoDivision of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. keisato@g.ecc.u-tokyo.ac.jp.ORCID 0000-0003-4431-1380
Takao HashiguchiLaboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan. hashiguchi.takao.1a@kyoto-u.ac.jp.ORCID 0000-0001-7578-7571
Kazuo TakayamaCenter for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan. kazuo.takayama@cira.kyoto-u.ac.jp.ORCID 0000-0002-1132-2457
Takasuke FukuharaDepartment of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan. fukut@pop.med.hokudai.ac.jp.ORCID 0000-0001-5471-8331
Kyoto University · JPThe University of Tokyo · JPHokkaido University · JPKumamoto University · JPSapporo University · JPTokyo Metropolitan Institute of Public Health · JPNational Institute of Infectious Diseases · JPUniversity of Miyazaki · JPHiroshima University · JPHokkaido University of Science · JPKobe University · JPKyushu University · JPSuez Canal University · EGTokai University · JP
Funding
Hokkaido University (HU) N/AJapan Agency for Medical Research and Development (AMED) JP21fk0108493Japan Agency for Medical Research and Development (AMED) JP21nf0101627Japan Agency for Medical Research and Development (AMED) JP22fk0108516Japan Agency for Medical Research and Development (AMED) JP22fk0108617Japan Agency for Medical Research and Development (AMED) JP22gm1610008MEXT | Japan Society for the Promotion of Science (JSPS) 21H02736MEXT | Japan Society for the Promotion of Science (JSPS) JP23K20041Takeda Medical Research Foundation N/A
Abstract
Circulation of SARS-CoV-2 Omicron XBB has resulted in the emergence of XBB.1.5, a new Variant of Interest. Our phylogenetic analysis suggests that XBB.1.5 evolved from XBB.1 by acquiring the S486P spike (S) mutation, subsequent to the acquisition of a nonsense mutation in ORF8. Neutralization assays showed similar abilities of immune escape between XBB.1.5 and XBB.1. We determine the structural basis for the interaction between human ACE2 and the S protein of XBB.1.5, showing similar overall structures between the S proteins of XBB.1 and XBB.1.5. We provide the intrinsic pathogenicity of XBB.1 and XBB.1.5 in hamsters. Importantly, we find that the ORF8 nonsense mutation of XBB.1.5 resulted in impairment of MHC suppression. In vivo experiments using recombinant viruses reveal that the XBB.1.5 mutations are involved with reduced virulence of XBB.1.5. Together, our study identifies the two viral functions defined the difference between XBB.1 and XBB.1.5.
Indexed as
COVID-19AnimalsBiological AssayCodon, NonsenseCricetinaeHumansPhylogenySARS-CoV-2Codon, Nonsense
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.